阿尔茨海默病外周血液生物标志物的研究进展

doi:10.3969/j.issn.1003-9198.2021.10.019

摘要/Abstract

中图分类号:

R 749.16

陈心怡, 孙杨, 徐德恩. 阿尔茨海默病外周血液生物标志物的研究进展[J]. 实用老年医学, 2021, 35(10): 1076-1079.

[1] FUKUMOTO H, TENNIS M, LOCASCIO J J, et al. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels[J]. Arch Neurol, 2003, 60(7):958-964.
[2] SONG F, POLJAK A, VALENZUELA M, et al. Meta-analysis of plasma amyloid-β levels in Alzheimer’s disease[J]. J Alzheimers Dis, 2011, 26(2):365-375.
[3] KIM H J, PARK K W, KIM T E, et al. Elevation of the plasma Aβ40/Aβ42 ratio as a diagnostic marker of sporadic early-onset Alzheimer’s disease[J]. J Alzheimers Dis, 2015, 48(4):1043-1050.
[4] JANELIDZE S, STOMRUD E, PALMQVIST S, et al. Plasma β-amyloid in Alzheimer’s disease and vascular disease[J]. Sci Rep, 2016, 6:26801.
[5] CHEN T B, LEE Y J, LIN S Y, et al. Plasma Aβ42 and total tau predict cognitive decline in amnestic mild cognitive impairment[J]. Sci Rep, 2019, 9(1): 13984.
[6] CHEN T B, LAI Y H, KE T L, et al. Changes in plasma amyloid and tau in a longitudinal study of normal aging, mild cognitive impairment, and Alzheimer’s disease[J]. Dement Geriatr Cogn Disord, 2019, 48(3/4):180-195.
[7] YANG Y H, HUANG L C, HSIEH S W, et al. Dynamic blood concentrations of Aβ1-40 and Aβ1-42 in Alzheimer’s disease[J]. Front Cell Dev Biol, 2020, 8:768.
[8] RISACHER S L, FANDOS N, ROMERO J, et al. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition[J]. Alzheimers Dement: Amst, 2019, 11:510-519.
[9] MATTSSON N, ZETTERBERG H, JANELIDZE S, et al. Plasma tau in Alzheimer disease[J]. Neurology, 2016, 87(17):1827-1835.
[10] YANG C C, CHIU M J, CHEN T F, et al. Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer’s disease[J]. J Alzheimers Dis, 2018, 61(4):1323-1332.
[11] MIELKE M M, HAGEN C E, WENNBERG A M V, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on Aging[J]. JAMA Neurol, 2017, 74(9): 1073-80.
[12] MIELKE M M, HAGEN C E, XU J, et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography[J]. Alzheimers Dement, 2018, 14(8):989-997.
[13] KARIKARI T K, BENEDET A L, ASHTON N J, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s disease neuroimaging initiative[J]. Mol Psychiatry, 2021, 26(2):429-442.
[14] THIJSSEN E H, LA JOIE R, WOLF A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration[J]. Nat Med, 2020, 26(3):387-397.
[15] LANTERO RODRIGUEZ J, KARIKARI T K, SUAREZ-CALVET M, et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline[J]. Acta Neuropathol, 2020, 140(3):267-278.
[16] JANELIDZE S, BERRON D, SMITH R, et al. Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease [J]. JAMA Neurol, 2020, 78(2):149-156.
[17] MATTSSON-CARLGREN N, JANELIDZE S, PALMQVIST S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease[J]. Brain, 2020, 143(11): 3234-3241.
[18] BARTHELEMY N R, HORIE K, SATO C, et al. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease[J]. J Exp Med, 2020, 217(11):e20200861.
[19] PALMQVIST S, JANELIDZE S, QUIROZ Y T, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders[J]. JAMA, 2020, 324(8):772-781.
[20] ASHTON N J, PASCOAL T A, KARIKARI T K, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology[J]. Acta Neuropathol, 2021, 141(5):709-724.
[21] WESTON P S J, POOLE T, RYAN N S, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration[J]. Neurology, 2017, 89(21): 2167-2175.
[22] KHALIL M, TEUNISSEN C E, OTTO M, et al. Neurofilaments as biomarkers in neurological disorders[J]. Nat Rev Neurol, 2018, 14(10):577-589.
[23] RAJAN K B, AGGARWAL N T, MCANINCH E A, et al. Remote blood biomarkers of longitudinal cognitive outcomes in a population study[J]. Ann Neurol, 2020, 88(6):1065-1076.
[24] SUGARMAN M A, ZETTERBERG H, BLENNOW K, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer’s disease[J]. Neurobiol Aging, 2020, 94:60-70.
[25] RAKET L L, KUHNEL L, SCHMIDT E, et al. Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer’s disease[J]. Alzheimers Dement: Amst, 2020, 12(1):e12099.
[26] BENUSSI A, KARIKARI T K, ASHTON N, et al. Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration[J]. J Neurol Neurosurg Psychiatry, 2020, 91(9):960-967.
[27] GUO R, FAN G, ZHANG J, et al. A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer’s disease[J]. J Alzheimers Dis, 2017, 60(4):1365-1377.
[28] YANG Q, ZHAO Q, YIN Y. miR-133b is a potential diagnostic biomarker for Alzheimer’s disease and has a neuroprotective role[J]. Exp Ther Med, 2019, 18(4):2711-2718.
[29] NAGARAJ S, ZOLTOWSKA K M, LASKOWSKA-KASZUB K, et al. MicroRNA diagnostic panel for Alzheimer’s disease and epigenetic trade-off between neurodegeneration and cancer[J]. Ageing Res Rev, 2019, 49:125-143.
[30] TAKOUSIS P, SADLON A, SCHULZ J, et al. Differential expression of microRNAs in Alzheimer’s disease brain, blood, and cerebrospinal fluid[J]. Alzheimers Dement, 2019, 15(11):1468-1477.
[31] ZHUANG J C, CAI P P, CHEN Z J, et al. Long noncoding RNA MALAT1 and its target microRNA-125b are potential biomarkers for Alzheimer’s disease management via interactions with FOXQ1, PTGS2 and CDK5[J]. Am J Transl Res, 2020, 12(9):5940-5954.
[32] YANG T T, LIU C G, GAO S C, et al. The serum exosome derived microRNA-135a, -193b, and -384 were potential Alzheimer’s disease biomarkers[J]. Biomed Environ Sci, 2018, 31(2):87-96.
[33] LI F, XIE X Y, SUI X F, et al. Profile of pathogenic proteins and microRNAs in plasma-derived extracellular vesicles in Alzheimer’s Disease: A Pilot Study[J]. Neuroscience, 2020, 432:240-246.

阿尔茨海默病外周血液生物标志物的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	孙丽, 尹卫红, 经俊, 钱夏丽. 亚麻醉剂量艾司氯胺酮对老年脊柱手术病人术后早期认知功能障碍的影响[J]. 实用老年医学, 2024, 38(10): 1039-1043.
[2]	董丽华, 李加梅, 郑加平, 雷小晶. 血液生物标志物在阿尔茨海默病早期诊断中的研究进展[J]. 实用老年医学, 2023, 37(12): 1249-1254.
[3]	张伟, 王蓉. 衰老作为神经退行性疾病危险因素的科学现状分析[J]. 实用老年医学, 2023, 37(10): 984-988.
[4]	时建铨, 郑慧芬, 徐畅, 王变荣. 认知障碍简明评价量表与Addenbrooke认知评估量表Ⅲ诊断阿尔茨海默病的准确性比较[J]. 实用老年医学, 2023, 37(10): 1041-1043.
[5]	阎子花, 杜静, 宋竹梅, 张兴梅, 张楠. 痴呆病人病感失认测评工具的研究进展[J]. 实用老年医学, 2023, 37(10): 1059-1063.
[6]	王琳琳, 杨诗怡, 徐俊. 人工智能在阿尔茨海默病中的研究进展[J]. 实用老年医学, 2023, 37(9): 869-872.
[7]	王敏, 郭文军, 汤忠泉, 赵晓敏, 欧婷, 李云涛. 听力障碍与阿尔茨海默病相关性的Meta分析[J]. 实用老年医学, 2023, 37(9): 915-919.
[8]	段景宜, 刘静, 查玉航, 杨巧露, 何海洋, 马亚男, 高海英. 阿尔茨海默病医防融合模式的探索[J]. 实用老年医学, 2023, 37(8): 757-760.
[9]	张绍敏, 吴锦晖. COVID-19与阿尔茨海默病的最新研究进展[J]. 实用老年医学, 2023, 37(5): 521-523.
[10]	赵璨, 冯美江. 外泌体与阿尔茨海默病的研究进展[J]. 实用老年医学, 2023, 37(4): 335-338.
[11]	朱贺, 殷实. 认知障碍与抑郁症关系的研究进展[J]. 实用老年医学, 2023, 37(3): 234-237.
[12]	郭晓娟, 刘洁, 王瑾, 陆文惠, 高玲, 屈秋民. 西安地区阿尔茨海默病病人药物依从性调查及影响因素分析[J]. 实用老年医学, 2023, 37(1): 47-50.
[13]	陈绍敏, 王英. 轻度认知功能障碍老年人阿尔茨海默病风险预测的研究进展[J]. 实用老年医学, 2021, 35(12): 1304-1308.
[14]	王桢, 冯美江. 阻塞性睡眠呼吸暂停低通气综合征和阿尔茨海默病相关性研究进展[J]. 实用老年医学, 2021, 35(8): 795-797.
[15]	高弈宁, 张少伟, 李霞. 正念练习应用于老年人认知功能干预的研究进展[J]. 实用老年医学, 2021, 35(8): 866-870.